Akeso lung cancer drug extends patient survivalextends patient survival in China trial
Chinese biotech company Akeso reported that its lung cancer drug ivonescimab helped patients live about four months longer in a late-stage trial in China.
The results strengthen interest in a closely watched cancer treatment class and could broaden the drug’s future use in a large global market.
Company and trial supporters
Akeso and backers of the drug present the result as evidence that ivonescimab is a serious contender in lung cancer care. They say the outcome could help the treatment reach more patients if regulators accept additional uses.
Competitive biotech market view
Observers focused on the sector see the findings as a sign that Chinese drug developers can challenge established international cancer therapies. They also note that strong results in one cancer subtype may affect pricing and future competition across a market worth tens of billions of dollars.
- Lung cancer is the leading cause of cancer deaths worldwide.
- Bispecific antibodies are a relatively new design compared with traditional single-target cancer drugs.
- China has become a major source of global clinical trial data in recent years.
